TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer.
Serum levels of CEA, CA 19.9 and TAG-72 were measured in 79 patients with active gastric cancer, 47 with treated gastric cancer and no clinical evidence of the disease and 33 with benign gastric disease. In the patients with active gastric cancer TAG-72 was increased in 47%, CA 19.9 in 46% and CEA in 33%. The sensitivity of these markers was related to the stage of the disease, although upon comparison of stages I-II and III-IV significant difference was observed only for TAG-72. The combined use of two of the markers increased the sensitivity compared with the use of only one. The results suggest that the combination of TAG-72 and CA 19.9 may be useful in the post surgical management of patients with gastric cancer.
Filella
X
X
Department of Clinical Biochemistry, Hospital Clínic i Provincial, Barcelona, Spain.
Fuster
J
J
Molina
R
R
Grau
J J
JJ
García-Valdecasas
J C
JC
Grande
L
L
Estapé
J
J
Ballesta
A M
AM
D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D009367:Neoplasm Staging; D012680:Sensitivity and Specificity; D013274:Stomach Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D006023:Glycoproteins; C047052:tumor-associated antigen 72